On January 30, 2026, Japanese pharmaceutical giant Daiichi Sankyo released its financial report for the third quarter of FY2025 (April 2025 - April 2026). The standout performance in the data was the strong sales of its flagship product, Enhertu (DS-8201), an antibody-drug conjugate (ADC). In the first three quarters of FY2025, Enhertu achieved sales of ￥506.8 billion, approximately $3.3 billion, marking a 25.3% year-on-year increase.
The company reported total revenue of ￥1.5335 trillion for the first three quarters of FY2025 (April 2025 - December 2025), a 12.1% growth year-on-year. Core operating profit reached ￥249.2 billion, an 8.8% increase compared to the previous year. As a company driven by innovation, Daiichi Sankyo is charting a unique growth path in the global pharmaceutical market through strategic planning and technological leadership.
Achieving $4.4 billion in global sales for Enhertu in 2025 is no small feat. The strong performance of this drug is a direct result of its growing clinical value across major markets. Enhertu is a third-generation ADC targeting HER2, and it has achieved a perfect balance between efficacy and stability with its unique DXd payload and cleavable linker design.
In December 2025, the FDA approved Enhertu in combination with Perjeta (pertuzumab) for the first-line treatment of HER2-positive metastatic breast cancer, based on groundbreaking data from the DESTINY-Breast09 study. This approval marked a significant milestone, shifting Enhertu from a later-line therapy to a first-line option, revolutionizing the treatment landscape. The study showed an impressive progression-free survival (PFS) of 29.0 months, compared to 7.8 months in the control group, along with a 5-year progression-free survival rate of 37.6% versus 10.0%, and a 5-year overall survival rate of 48.1% versus 36.9%. These data not only confirm Enhertu's long-lasting efficacy and manageable safety but also highlight its potential as a cornerstone drug for advanced breast cancer.
In terms of market penetration, Enhertu has already achieved coverage in major healthcare systems across the globe, with its market share for new patients remaining the highest. In the U.S., following its approval for first-line use, the drug quickly gained market traction, with full commercialization efforts ramping up in December 2025. The drug also received marketing applications in Japan and China in October and November 2025, respectively, with the European Union simultaneously advancing its review process. Thanks to the Project Orbis framework, Enhertu underwent concurrent regulatory reviews across multiple agencies, significantly reducing time-to-market globally.
Furthermore, the NCCN guidelines have continuously expanded its clinical indications—from a Category 1 recommendation for high-risk adjuvant therapy to a Category 2A recommendation for HER2-positive endometrial cancer treatment beyond the second line, continuously broadening its clinical usage. Currently, Enhertu is approved for breast cancer, gastric cancer, and lung cancer, and is undergoing nearly 20 phase III trials for a wide range of cancers, such as ovarian, endometrial, and esophageal cancers. Its "one drug, multiple cancers" strategy is moving from concept to reality.
As Enhertu continues its impressive growth, Daiichi Sankyo’s second growth driver—Datroway (Dato-DXd), an ADC targeting TROP2—is also showing explosive potential. In FY2025 Q3, global sales for Datroway reached ￥31.6 billion, a significant leap from zero. While still far behind Enhertu in absolute sales, this marks the successful market introduction of the new product.
Notably, based on data from the TROPION-Breast02 study, Datroway filed for marketing approval in December 2025 in both China and the European Union as a first-line treatment for metastatic triple-negative breast cancer (mTNBC) in patients who are not suitable for PD-1/PD-L1 inhibitors. This differentiated indication avoids direct competition with immunotherapies and precisely addresses a clinical gap.
The strategic value of Datroway extends beyond breast cancer. In non-small cell lung cancer (NSCLC), the TROPION-Lung01 study confirmed its significant benefit for patients with no driver gene mutations and PD-L1 expression below 50%. A January 2026 TROPION-Lung17 study introduced the innovative use of TROP2 NMR (membrane protein ratio) biomarkers to select patients for precision treatment, a biomarker-driven development strategy that enhances the success rate of clinical trials and provides strong evidence for future health insurance negotiations.
In addition, multiple phase III studies are progressing for indications such as EGFR-mutated NSCLC after treatment failure and bladder cancer after platinum-based chemotherapy. Datroway is following the successful path of Enhertu and is expanding its reach across multiple solid tumor indications.
Daiichi Sankyo’s true competitive advantage lies in its unique 5DXd ADC technology platform. This platform includes ADCs such as Enhertu, Datroway, HER3-DXd, I-DXd (targeting B7-H3), and R-DXd (targeting CDH6), as well as early-stage investigational products like DS-6000 and DS-3939. In FY2025 Q3, the 5DXd ADC portfolio generated ￥613.6 billion in revenue, a 25.3% year-on-year increase, accounting for over 40% of the company’s total revenue, solidifying its role as a key growth engine.
The core strength of this platform lies in its modular design and reproducibility. The DXd payload's topoisomerase I inhibitor mechanism, the stability and uniformity of the cleavable four-peptide linker, and the drug-antibody ratio (DAR) of up to 8 together form the foundation of an efficient, low-toxicity platform. From HER2 to TROP2, and from HER3 to B7-H3 and CDH6, Daiichi Sankyo has demonstrated its ability to rapidly replicate a successful model across different targets.
This platform capability not only reduces the development risk for subsequent projects but also creates a strong, complementary market ecosystem through its diverse indications. For example, in breast cancer, Enhertu targets HER2-positive and low-expression patients, while Datroway focuses on triple-negative breast cancer, forming a seamless connection between the two; in lung cancer, various biomarkers, including HER2 mutations, TROP2 expression, and HER3 resistance, are addressed with corresponding ADC products, offering clinicians a tailored, individualized treatment menu.
The recent victory in a patent dispute with Seagen further solidified the value of this platform. In December 2025, the U.S. Federal Circuit Court of Appeals overturned a Texas court’s decision that Enhertu infringed on Seagen’s patents and ruled that Seagen's patents were invalid. This ruling not only spared Daiichi Sankyo from potentially billions of dollars in damages but also cleared the legal obstacles for its ADC platform in the U.S. market. The patent win confirmed the independence of the DXd-ADC technology pathway, eliminating the need to pay premium prices for patent risks, thus significantly enhancing the commercial valuation of the platform.
Daiichi Sankyo’s FY2025 Q3 financial report tells a complete success story that goes far beyond the $4.4 billion in sales or ￥613.6 billion in ADC portfolio revenue. It reflects a pharmaceutical company that has successfully translated platform technology into clinical value and then converted that clinical value into a formidable business barrier. From the disruption of HER2-positive tumor treatments with Enhertu, to the rapid expansion of Datroway in TROP2, to the decisive patent dispute victory clearing legal hurdles, and the bold exploration of epigenetics and protein degradation in its Next Wave pipeline, Daiichi Sankyo is leading the golden age of ADC medicines.
While global pharmaceutical giants are increasingly entering the ADC space through mergers and collaborations, Daiichi Sankyo has established an almost insurmountable competitive barrier thanks to its first-mover advantage and platform depth. Over the next five years, with the full bloom of the 5DXd ADC pipeline across breast cancer, lung cancer, and gastrointestinal tumors, as well as the emergence of next-generation products like EZHARMIA and DS-9051, Daiichi Sankyo’s growth ceiling will continue to be pushed higher and higher.
[1]. https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/Q3/FY2025Q3_Financial_Results_Presentation_E.pdf
